MI
MIRM.O
—
NASDAQ
Pharmaceuticals
Mirm.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-4,2 %
ROE
-7,4 %
Net margin
-4,5 %
Debt / equity
0,98
Beta
—
52w range
—
Volume
195
Day range
$94,34–$97,43
Prev close
$97,33
Open
$96,65
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare and severe liver diseases.
Business. Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare and severe liver diseases.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY11 analysts
11 buy0 hold0 sell
Avg 12m price target129,73
Analyst recommendations
11 analysts · consensus BuyBuy11
Hold0
Sell0
12-month price target
129,73
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
11 analysts · indicative
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
-7,4 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to MIRM.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare and severe liver diseases.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDMirum Pharmaceuticals has a liquidity position characterized by $296.68 million in cash and equivalents, which is offset by $309.80 million in long-term debt, resulting in a net cash position of -$13.12 million. The company's debt-to-equity ratio of 0.98 suggests a moderate level of leverage, while its current ratio of 2.67 indicates a strong ability to meet short-term obligations.
The company's profitability metrics are concerning, with a return on equity of -7.42% and a return on assets of -2.77%. These figures are below the industry norms for pharmaceutical companies, which typically exhibit positive returns on equity and assets. The negative operating income of $22.14 million and net loss of $23.36 million further underscore the company's current financial challenges.
Mirum Pharmaceuticals operates in a single business segment focused on the development of therapies for rare liver diseases. The company's geographic exposure is primarily concentrated in the United States, with no significant international revenue disclosed. This concentration may expose the company to regulatory and market risks specific to the U.S. healthcare environment.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. However, the negative operating cash flow and free cash flow of $55.83 million and -$73,000, respectively, suggest that the company is not generating sufficient cash from operations to sustain or grow its business without external financing.
The risk assessment for Mirum Pharmaceuticals highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates potential liquidity constraints. The company's dilution risk is considered low, but the negative free cash flow and reliance on operating cash flow suggest that the company may need to raise additional capital in the future, which could lead to share dilution.
Recent events and filings indicate that Mirum Pharmaceuticals is actively engaged in clinical trials and regulatory submissions for its lead candidate, MARZAA (maralixibat). The company has also been in discussions with the U.S. Food and Drug Administration (FDA) regarding the potential approval of MARZAA for the treatment of progressive familial intrahepatic cholestasis (PFIC).
Key takeaways
- Mirum Pharmaceuticals has a strong current ratio of 2.67, indicating a solid short-term liquidity position despite a negative net cash position.
- The company's return on equity and return on assets are negative, reflecting poor profitability and underperformance relative to industry standards.
- Mirum Pharmaceuticals operates in a single business segment focused on rare liver diseases, with a primary geographic concentration in the United States.
- The company's negative free cash flow and reliance on operating cash flow suggest a need for external financing to support ongoing operations and growth.
- The risk assessment indicates a medium liquidity risk and a low dilution risk, with the key flag of negative net cash after subtracting total debt being a significant concern.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$104,59
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$314.7M
Net cashⓘ
-$13.1M
Current ratioⓘ
2.7
Debt / equityⓘ
1.0
ROAⓘ
-2.8%
ROEⓘ
-7.4%
Cash conversionⓘ
-239.0%
CapEx / revenueⓘ
-0.2%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships5 disclosed relationships · 2 types · extracted from filings & disclosures
Partners4
NOVARTIS AGNVS.OPartner95%Source ↗
Pfizer IncPFE.TOPartner95%Source ↗
Travere Therapeutics IncTVTX.OPartner95%Source ↗
Vendors1
LONZA GROUP AGLON.NLBVendor95%Source ↗
Supply chain
Vendors → MIRM ↔ Partners → Customers · click any node to drill
5 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs MIRM · multiples and returns
JN
JNJ—
Johnson & Johnson
$254,43
622,1B USDP/E
23,5x
— vs self
Div yield
2,0 %
— vs self
ROE
33,0 %
+40,4 vs self
LL
LLY—
ELI LILLY AND COMPANY
$1 124,04
1,01T USDP/E
52,0x
— vs self
Div yield
0,5 %
— vs self
ROE
66,2 %
+73,6 vs self
MR
MRK—
MERCK & CO., INC.
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
PF
PFE—
Pfizer Inc
$25,05
143,6B USDP/E
18,2x
— vs self
Div yield
6,9 %
— vs self
ROE
8,6 %
+16,0 vs self
AB
ABBV—
Abbvie Inc
$245,10
434,8B USDP/E
110,6x
— vs self
Div yield
2,5 %
— vs self
ROE
-63,5 %
-56,1 vs self
AZ
AZN—
AZN.L
$157,59
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BM
BMY—
Bristol-myers Squibb Co
$65,60
134,3B USDP/E
17,7x
— vs self
Div yield
4,1 %
— vs self
ROE
31,6 %
+39,0 vs self
GS
GSK—
Gsk Plc-spon Adr
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 36 %
EPS
Consensus EPS
-1,77
Predicted surprise
-0,02
Beat probability
36 %
Analysts
11
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-06 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,77 |
| Revenue | —no estimate | —no estimate | 644,9M USD |
| Operating income | —no estimate | —no estimate | -79,1M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution11 analysts
Strong buy4
Buy7
Hold0
Sell0
Strong sell0
12-month price target$129,73 · Median $130,00
Low $112,00High $150,00
Operating income · consensus-79,1M USD
EPS surprise
+73,4 %
reported vs consensus · beat
Revenue surprise
−19,2 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$112,00
Mean$129,73
Median$130,00
High$150,00
Spot$104,59
+24.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-4,2 %Below median
Net Margin-4,5 %Below median
ROE-7,4 %Bottom quartile
Capex / Rev-0,2 %Above P75
D/E0,98Bottom quartile
Cash Conv-2,39Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 191 731 sh20 exercises · 16 grants13 insiders
- Director, CHIEF EXECUTIVE OFFICER · Employee Stock Option (right to buy) → Common StockDisposed 20 000 @ $2,94exercise · 2026-07-06
- Director · Restricted Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Restricted Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Restricted Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Deferred Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Deferred Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Deferred Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- Director · Stock Option (right to buy) → Common StockAcquired 3 772 @ $101,00grant · 2026-06-15
- Director · Deferred Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- Director · Restricted Stock Units → Common StockAcquired 1 980grant · 2026-06-15
- CHIEF FINANCIAL OFFICER · Employee Stock Option (right to buy) → Common StockDisposed 2 393 @ $26,49exercise · 2026-06-09
- PRESIDENT AND COO · Stock Option (right to buy) → Common StockDisposed 16 988 @ $19,19exercise · 2026-06-05
- Director, CHIEF EXECUTIVE OFFICER · Employee Stock Option (right to buy) → Common StockDisposed 30 000 @ $2,94exercise · 2026-06-01
- Director · Restricted Stock Units → Common StockDisposed 3 977exercise · 2026-05-29
- Director · Restricted Stock Units → Common StockDisposed 3 977exercise · 2026-05-29
- Director · Restricted Stock Units → Common StockDisposed 3 977exercise · 2026-05-29
- Director · Restricted Stock Units → Common StockDisposed 3 977exercise · 2026-05-29
- Director · Stock Option (right to buy) → Common StockDisposed 2 000 @ $23,51exercise · 2026-05-15
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- MIRM.O Market data — financials · 2026-05-28
- Mirum Pharmaceuticals Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,31 %$627M
- Investment Managers · as of 2026-03-310,02 %$123M
- Investment Managers · as of 2026-03-310,02 %$0M
- Investment Managers · as of 2026-03-310,01 %$14M
- Institutional Investor · as of 2026-03-310,01 %$54M
- Institutional Investor · as of 2026-03-310,01 %$182M
- Investment Managers · as of 2026-03-310,01 %$67M
- Institutional Investor · as of 2026-03-310,01 %$26M
- Investment Managers · as of 2024-12-310,01 %$30M
- Investment Managers · as of 2026-03-310,01 %$61M
- Investment Managers · as of 2026-03-310,01 %$116M
- Brokerage Firms · as of 2026-03-310,01 %$21M
- Investment Managers · as of 2026-03-310,01 %$180M
- Investment Managers · as of 2026-03-310,01 %$39M
- Investment Managers · as of 2026-03-310,01 %$9M
- Investment Managers · as of 2026-03-310,00 %$36M
- Institutional Investor · as of 2026-03-310,00 %$20M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2025-12-310,00 %$205M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$4M
- Funds · as of 2026-03-310,00 %$3M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 28 sellsnet -$15,0M9 insiders · last 365d
- CHIEF FINANCIAL OFFICER · Common StockSold 300 @ $124,94$37K · 2026-07-06
- CHIEF FINANCIAL OFFICER · Common StockSold 528 @ $123,84$65K · 2026-07-06
- CHIEF FINANCIAL OFFICER · Common StockSold 1 048 @ $122,43$128K · 2026-07-06
- CHIEF FINANCIAL OFFICER · Common StockSold 3 124 @ $121,67$380K · 2026-07-06
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 1 710 @ $124,79$213K · 2026-07-06
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 1 975 @ $123,74$244K · 2026-07-06
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 4 181 @ $122,34$512K · 2026-07-06
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 12 134 @ $121,65$1,5M · 2026-07-06
- Director, CHIEF EXECUTIVE OFFICER · Common StockOther 20 000 @ $2,94$59K · 2026-07-06
- SVP, GLOBAL CONTROLLER · Common StockSold 2 721 @ $120,00$327K · 2026-07-01
- SVP, GLOBAL CONTROLLER · Common StockSold 2 594 @ $101,95$264K · 2026-06-17
- CHIEF FINANCIAL OFFICER · Common StockOther 2 393 @ $26,49$63K · 2026-06-09
- CHIEF FINANCIAL OFFICER · Common StockSold 1 175 @ $93,95$110K · 2026-06-08
- CHIEF FINANCIAL OFFICER · Common StockSold 2 258 @ $92,84$210K · 2026-06-08
- CHIEF FINANCIAL OFFICER · Common StockSold 1 567 @ $95,12$149K · 2026-06-08
- PRESIDENT AND COO · Common StockOther 16 988 @ $19,19$326K · 2026-06-05
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 2 602 @ $94,64$246K · 2026-06-01
- Director · Common StockSold 3 977 @ $100,00$398K · 2026-06-01
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 16 595 @ $95,34$1,6M · 2026-06-01
- Director, CHIEF EXECUTIVE OFFICER · Common StockOther 30 000 @ $2,94$88K · 2026-06-01
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 1 973 @ $97,56$192K · 2026-06-01
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 1 021 @ $98,20$100K · 2026-06-01
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 883 @ $99,66$88K · 2026-06-01
- Director, CHIEF EXECUTIVE OFFICER · Common StockSold 6 926 @ $96,15$666K · 2026-06-01
- Director · Common StockOther 3 977 · 2026-05-29
Short positioning
7.3Mshares short-2.8% vs prior
10.59days to cover
49.5%short of daily vol
899fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
MIRM.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorPartnersVendors
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 25.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 440.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 74.7%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 54.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 39.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
- Net margin (FY 2025-12-31): -4.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -7.4%Derived (calculated)
- Return on assets (FY 2025-12-31): -2.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.67xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.68xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -3.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 33.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 74.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 74.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 73.4%Derived (calculated)
- Current liabilities (annual): USD 205.8MSEC XBRL filing
- Total operating expenses (annual): USD 543.45MSEC XBRL filing
- Current assets (annual): USD 549.68MSEC XBRL filing
- Pre-tax income (annual): USD -21.43MSEC XBRL filing
- Shareholders' equity (annual): USD 314.69MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Cash & equivalents (annual): USD 296.68MSEC XBRL filing
- Operating cash flow (annual): USD 55.83MSEC XBRL filing
Showing 24 of 53 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-06INSIDERBJERKHOLT ERIC sold 300 sh — CHIEF FINANCIAL OFFICER ~$37k
2026-07-06INSIDERBJERKHOLT ERIC sold 528 sh — CHIEF FINANCIAL OFFICER ~$65k
2026-07-06INSIDERBJERKHOLT ERIC sold 1.0k sh — CHIEF FINANCIAL OFFICER ~$128k
2026-07-06INSIDERBJERKHOLT ERIC sold 3.1k sh — CHIEF FINANCIAL OFFICER ~$380k
2026-07-06INSIDERPeetz Christopher sold 1.7k sh — Director, CHIEF EXECUTIVE OFFICER ~$213k
2026-07-06INSIDERPeetz Christopher sold 2.0k sh — Director, CHIEF EXECUTIVE OFFICER ~$244k
2026-07-06INSIDERPeetz Christopher sold 4.2k sh — Director, CHIEF EXECUTIVE OFFICER ~$512k
2026-07-06INSIDERPeetz Christopher sold 12.1k sh — Director, CHIEF EXECUTIVE OFFICER ~$1.48M
2026-07-06INSIDERPeetz Christopher transacted 20.0k sh — Director, CHIEF EXECUTIVE OFFICER ~$59k
2026-07-06INSIDERPeetz Christopher disposed of 20.0k sh Employee Stock Option (right to buy) — Director, CHIEF EXECUTIVE OFFICER
2026-07-01INSIDERHowe Jolanda sold 2.7k sh — SVP, GLOBAL CONTROLLER ~$327k
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-17 00:00 UTCINSIDER33 insider transactions — 2026-06 · net sell $3.5M 19 derivative
2026-06-17 00:00 UTCINSIDER33 insider transactions — 2026-06 · net sell $3.5M 19 derivative
2026-06-17INSIDERHowe Jolanda sold 2.6k sh — SVP, GLOBAL CONTROLLER ~$264k
2026-06-15INSIDERFairey William acquired 2.0k sh Deferred Stock Units — Director
2026-06-15INSIDERCardon Lon acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERCardon Lon acquired 2.0k sh Restricted Stock Units — Director
2026-06-15INSIDERRamasastry Saira acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERRamasastry Saira acquired 2.0k sh Restricted Stock Units — Director
2026-06-15INSIDERFairey William acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERBrege Laura acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERBrege Laura acquired 2.0k sh Deferred Stock Units — Director
2026-06-15INSIDERHeron Patrick J acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERHeron Patrick J acquired 2.0k sh Deferred Stock Units — Director
2026-06-15INSIDERFischer Laurent acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERFischer Laurent acquired 2.0k sh Deferred Stock Units — Director
2026-06-15INSIDERGREY MICHAEL G acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERGREY MICHAEL G acquired 2.0k sh Restricted Stock Units — Director
2026-06-15INSIDERWalbert Timothy P acquired 3.8k sh Stock Option (right to buy) — Director
2026-06-15INSIDERWalbert Timothy P acquired 2.0k sh Restricted Stock Units — Director
2026-06-09INSIDERBJERKHOLT ERIC transacted 2.4k sh — CHIEF FINANCIAL OFFICER ~$63k
2026-06-09INSIDERBJERKHOLT ERIC disposed of 2.4k sh Employee Stock Option (right to buy) — CHIEF FINANCIAL OFFICER
2026-06-08INSIDERBJERKHOLT ERIC sold 1.2k sh — CHIEF FINANCIAL OFFICER ~$110k
2026-06-08INSIDERBJERKHOLT ERIC sold 2.3k sh — CHIEF FINANCIAL OFFICER ~$210k
2026-06-08INSIDERBJERKHOLT ERIC sold 1.6k sh — CHIEF FINANCIAL OFFICER ~$149k
2026-06-05INSIDERRadovich Peter transacted 17.0k sh — PRESIDENT AND COO ~$326k
Showing the 40 most recent of 63 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage